| Identification | Back Directory | [Name]
Tigilanol tiglate | [CAS]
943001-56-7 | [Synonyms]
EBC46
EBC-46
EBC 46
Tigilanol tiglate
(1cS,2aR,3S,3aS,6bR,7R,8R,8aS)-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-8a-((2-methylbutanoyl)oxy)-4-oxo-1a
2-Butenoic acid, 2-methyl-, (1aR,1bR,1cS,2aR,3S,3aS,6aS,6bR,7R,8R,8aS)-1a,1b,1c,2a,3,3a,4,6a,6b,7,8,8a-dodecahydro-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-8a-[(2S)-2-methyl-1-oxobutoxy]-4-oxo-1H-cyclopropa[5',6']benz[1',2':7,8]azuleno[5,6-b]oxiren-8-yl ester, (2E)- | [Molecular Formula]
C30H42O10 | [MOL File]
943001-56-7.mol | [Molecular Weight]
562.65 |
| Chemical Properties | Back Directory | [Boiling point ]
682.1±55.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
10?+-.0.70(Predicted) | [color ]
White to off-white | [InChIKey]
YLQZMOUMDYVSQR-FOWZUWBHSA-N | [SMILES]
C(O[C@H]1[C@@]2(OC(=O)[C@@H](C)CC)C(C)(C)[C@@]2([H])[C@]2([H])[C@]3([H])O[C@]3(CO)[C@@H](O)[C@@]3(O)[C@@]([H])(C=C(C)C3=O)[C@@]2(O)[C@@H]1C)(=O)/C(/C)=C/C |
| Hazard Information | Back Directory | [Description]
Tigilanol tiglate is a novel small molecule drug approved in Europe for the intratumoural treatment of non-metastatic, unresectable canine mast cell tumours. In addition, Tigilanol tiglate is also used for the treatment of multiple synchronous mast cell tumours in dogs and skin tumours in horses. | [Uses]
Tigilanol tiglate is a medication used to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs). | [Definition]
ChEBI: Tigilanol tiglate is a diterpenoid natural product isolated from the kernels of the Australian blushwood tree (Fontainea picrosperma). It is approved as a veterinary pharmaceutical for the treatment of non-metastatic and non-resectable canine mast cell tumours. It has a role as an antineoplastic agent, a plant metabolite and a protein kinase C agonist. It is a diterpenoid, a phorbol ester, a diester and an organic heteropentacyclic compound. | [Mechanism of action]
The active substance in Tigilanol tiglate stimulates the action of enzymes called protein kinase C which are involved in regulating processes that can help cells grow and survive. By activating these enzymes blood supply to cells gets interrupted, resulting in the death of the cell. By injecting Stelfonta into the tumour, cancer cells will be affected, so destroying the tumour, and leaving a wound at the injection site. | [in vivo]
Tigilanol tiglate (66.5-533 μM, 50 μL, intratumorally) rapidly ablates melanoma xenograft tumors in a concentration dependent manner in BALB/c Foxn1nu nude mice[1].
Tigilanol tiglate (1 mg/mL, 0.5 mL per cm3 of tumor volume, intratumoral) is highly efficacious for the improvement of mast cell tumors in dogs[2].
|
|
|